Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyHead and Neck OncologyThoracic TumorsTumor, regardless of entityDiseaseLung Carcinoma, Non-Small CellThyroid CancerTumor Biomarker DefinedSubgroupHER2+RET fusion positiveROS1+ICD10C34.-C73MeSHNeoplasmsThyroid NeoplasmsSequenceTRIDENT-1: REPO160, NSCLC, C1 (PID554) -|- REPO160, NSCLC, C2+ (PID555)ChemotherapyChemo-substanceRepotrectinibSelpercatinibTrastuzumab emtansineChemo-substanceRepotrectinibSelpercatinibTrastuzumab emtansineChemo-substanceRepotrectinibSelpercatinibTrastuzumab emtansineChemo-substanceRepotrectinibSelpercatinibTrastuzumab emtansineNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaConstipationDiarrheaDizzinessEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)HeadacheHepatotoxicityHypertensionIncrease AminotransferasesIncrease Creatinine PhosphokinaseNeuropathyNeutropeniaParesthesiaPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorDrilon AJhaveri KLDiseaseNSCLC fortgeschritten oder metastasiert, ROS1+, ECOG 0-1RET-bedingte Tumoren, Zweitlinie oder höher, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, LIBRETTO-001Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, TRIDENT-1 trialProtocols in Revision 4 protocols foundRepotrectinib 160, Non-Small Cell Lung Cancer, Cycle 1 (PID554 V2.0)Repotrectinib 160, Non-Small Cell Lung Cancer, Cycle 2+ (PID555 V2.0)Selpercatinib 160, Tumor Biomarker Defined (PID1732 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
